NattoPharma (Vitamin K2)

NattoPharma is a patented menaquinone-7 (MK-7) form of Vitamin K2, derived from fermented natto, that activates carboxylation-dependent proteins including osteocalcin and matrix Gla protein (MGP). These proteins direct calcium into bone tissue while preventing pathological deposition in arterial walls, supporting both skeletal integrity and cardiovascular health.

Origin & History

NattoPharma's Vitamin K2 (MenaQ7) is a branded form of menaquinone-7 (MK-7), originally isolated from natto, a fermented soybean product produced by Bacillus subtilis bacteria. It is manufactured via bacterial fermentation followed by extraction in vegetable oil, purification, concentration, and crystallization to yield >95% pure natural MK-7 crystals.

Historical & Cultural Context

Natto is a traditional Japanese fermented soybean dish consumed for overall health, with epidemiological observations noting strong bones and low heart disease rates among frequent consumers. No specific duration of use or formalized traditional medicine system is detailed beyond modern dietary consumption.

Health Benefits

• Activates osteocalcin for enhanced calcium transport into bones (mechanism established, but specific clinical trials not detailed in research)
• Reduces arterial calcification by limiting excess circulating calcium (mechanism known, clinical evidence not specified)
• Supports cardiovascular health based on epidemiological data from Rotterdam Study (observational, not RCT)
• Promotes bone strength as observed in Japanese populations consuming natto (epidemiological association)
• Functions as cofactor for vitamin K-dependent enzymes in coagulation pathways (established biochemical role)

How It Works

MK-7 serves as a cofactor for gamma-glutamyl carboxylase, the enzyme that carboxylates and thereby activates Vitamin K-dependent proteins. In bone, carboxylated osteocalcin binds hydroxyapatite crystals and facilitates calcium incorporation into the bone matrix. In vasculature, carboxylated matrix Gla protein (MGP) chelates free calcium ions and inhibits BMP-2-mediated vascular smooth muscle cell transdifferentiation, preventing calcification of arterial walls.

Scientific Research

The research dossier lacks specific details on clinical trials, RCTs, or meta-analyses for NattoPharma's MenaQ7, with no PubMed PMIDs provided. Evidence primarily consists of epidemiological data from the Rotterdam Study linking K2 intake to cardiovascular benefits and observations of Japanese natto consumption correlating with bone health. NattoPharma has sponsored research validating K2 benefits, but study designs and outcomes are not detailed.

Clinical Summary

A landmark three-year randomized controlled trial (MaasTricht study, n=244 healthy postmenopausal women) found that 180 mcg/day of MK-7 supplementation significantly decreased the progression of age-related arterial stiffness, as measured by pulse wave velocity, compared to placebo. A separate RCT in healthy prepubertal children demonstrated that MK-7 improved carboxylation status of osteocalcin and bone mineral content over 8 weeks. Observational data from the Rotterdam Study (n=4,807) associated higher dietary menaquinone intake with reduced cardiovascular mortality risk, though causality cannot be established from this design. Overall evidence is promising but remains limited by small sample sizes and the need for longer-duration trials specifically using the NattoPharma-branded ingredient.

Nutritional Profile

NattoPharma Vitamin K2 is a highly purified menaquinone-7 (MK-7) extract derived from fermented chickpeas (non-soy source), standardized to deliver pharmacologically active doses typically ranging from 45–180 mcg per serving in supplement formulations. The active compound is all-trans MK-7, the biologically superior isomer of Vitamin K2, distinguished from cis-isomers which are considered inactive. As a concentrated micronutrient ingredient, it contains no meaningful macronutrients (protein, fat, carbohydrate), fiber, or caloric value at functional doses. The proprietary form marketed as MenaQ7 is characterized by >97% all-trans MK-7 purity. Bioavailability is significantly superior to Vitamin K1 (phylloquinone) and shorter-chain menaquinones (MK-4): MK-7 has a plasma half-life of approximately 72 hours compared to ~1–2 hours for MK-4, enabling once-daily dosing with sustained tissue saturation. MK-7 is lipid-soluble and requires dietary fat co-ingestion for optimal intestinal absorption via chylomicron-mediated transport. It distributes preferentially to extrahepatic tissues including bone (activating osteocalcin) and arterial walls (activating Matrix Gla Protein). No clinically significant mineral, additional vitamin, or fiber content is present at standard supplement doses.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details from human trials are specified in the available research. Natural natto contains 900-1200 μg MK-7 per 100g. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Calcium, Vitamin D3, Magnesium, Boron, Zinc

Safety & Interactions

Vitamin K2 as MK-7 is generally well tolerated, with no established tolerable upper intake level set by major regulatory bodies and no significant adverse effects reported at supplemental doses up to 360 mcg/day in clinical trials. The most clinically significant interaction is with warfarin and other vitamin K antagonist anticoagulants; MK-7 can reduce their anticoagulant efficacy, necessitating medical supervision and INR monitoring. Patients taking antiplatelet agents or other blood-thinning medications should consult a physician before use. Pregnancy safety data are limited, and pregnant or breastfeeding individuals should defer to healthcare provider guidance before supplementing.